by Jay Achar, Cathy Hewison, Ana P. Cavalheiro et al.
Emerging Infectious Diseases, Vol. 23, No. 10, October 2017
The authors describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. They report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.